Debanjana Chatterjee
Stock Analyst at JonesTrading
(4.90)
# 261
Out of 5,058 analysts
260
Total ratings
58.1%
Success rate
33.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Reiterated: Buy | $26 → $30 | $7.08 | +323.73% | 17 | Oct 14, 2026 | |
| EYPT EyePoint | Reiterated: Buy | $20 | $2.99 | +568.90% | 31 | Oct 7, 2026 | |
| IRD Opus Genetics | Rated: Buy | $10 → $17 | $3.84 | +342.71% | 25 | Oct 5, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $121 → $130 | $79.90 | +62.70% | 22 | Oct 1, 2026 | |
| ABCL AbCellera Biologics | Reiterated: Buy | $25 | $11.80 | +111.86% | 9 | Sep 27, 2026 | |
| ARMP Armata Pharmaceuticals | Reiterated: Buy | $20 | $3.37 | +493.47% | 7 | Sep 27, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $31 | $8.02 | +286.53% | 19 | Sep 27, 2026 | |
| HYFT MindWalk Holdings | Reiterated: Buy | $5 | $1.31 | +281.68% | 3 | Sep 15, 2026 | |
| TVRD Tvardi Therapeutics | Reiterated: Buy | $12 → $10 | $1.01 | +890.10% | 18 | Sep 15, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $52 → $65 | $27.74 | +134.32% | 15 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $2.62 | +510.69% | 4 | Aug 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.83 | +253.36% | 4 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $11.42 | +153.94% | 28 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $24 → $28 | $11.88 | +135.69% | 22 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $8.25 | +57.58% | 19 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $3.89 | +1,519.54% | 9 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.023 | - | 8 | May 22, 2026 |
Contineum Therapeutics
Oct 14, 2026
Reiterated: Buy
Price Target: $26 → $30
Current: $7.08
Upside: +323.73%
EyePoint
Oct 7, 2026
Reiterated: Buy
Price Target: $20
Current: $2.99
Upside: +568.90%
Opus Genetics
Oct 5, 2026
Rated: Buy
Price Target: $10 → $17
Current: $3.84
Upside: +342.71%
Spyre Therapeutics
Oct 1, 2026
Rated: Buy
Price Target: $121 → $130
Current: $79.90
Upside: +62.70%
AbCellera Biologics
Sep 27, 2026
Reiterated: Buy
Price Target: $25
Current: $11.80
Upside: +111.86%
Armata Pharmaceuticals
Sep 27, 2026
Reiterated: Buy
Price Target: $20
Current: $3.37
Upside: +493.47%
Sagimet Biosciences
Sep 27, 2026
Reiterated: Buy
Price Target: $31
Current: $8.02
Upside: +286.53%
MindWalk Holdings
Sep 15, 2026
Reiterated: Buy
Price Target: $5
Current: $1.31
Upside: +281.68%
Tvardi Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $12 → $10
Current: $1.01
Upside: +890.10%
Pharvaris
Sep 9, 2026
Reiterated: Buy
Price Target: $52 → $65
Current: $27.74
Upside: +134.32%
Aug 28, 2026
Reiterated: Buy
Price Target: $16
Current: $2.62
Upside: +510.69%
Aug 21, 2026
Reiterated: Buy
Price Target: $10
Current: $2.83
Upside: +253.36%
Aug 14, 2026
Reiterated: Buy
Price Target: $29
Current: $11.42
Upside: +153.94%
Aug 13, 2026
Rated: Buy
Price Target: $24 → $28
Current: $11.88
Upside: +135.69%
Aug 12, 2026
Reiterated: Buy
Price Target: $13
Current: $8.25
Upside: +57.58%
Aug 10, 2026
Downgraded: Hold
Price Target: $63
Current: $3.89
Upside: +1,519.54%
May 22, 2026
Rated: Hold
Price Target: n/a
Current: $0.023
Upside: -